148 related articles for article (PubMed ID: 37559593)
1. Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease.
Liu M; Christ L; Richters A; Özdemir BC
Oncol Lett; 2023 Sep; 26(3):377. PubMed ID: 37559593
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
[TBL] [Abstract][Full Text] [Related]
3. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
4. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
[TBL] [Abstract][Full Text] [Related]
6. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
8. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
9. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
10. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
11. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
12. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
Barron CC; Stefanova I; Cha Y; Elsolh K; Zereshkian A; Gaafour N; McWhirter E
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536939
[TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of immune checkpoint inhibitors in patients with preexisting organ dysfunction.
Kesireddy M; Marr A; Schissel M; Ganti AK
Cancer; 2023 Nov; 129(22):3603-3619. PubMed ID: 37548033
[TBL] [Abstract][Full Text] [Related]
15. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
Kumar R; Chan A; Bandikatla S; Ranjan S; Ngo P
Curr Probl Cancer; 2022 Aug; 46(4):100864. PubMed ID: 35671576
[TBL] [Abstract][Full Text] [Related]
16. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.
Yamaguchi A; Saito Y; Okamoto K; Narumi K; Furugen A; Takekuma Y; Sugawara M; Kobayashi M
Support Care Cancer; 2021 Dec; 29(12):7747-7753. PubMed ID: 34164739
[TBL] [Abstract][Full Text] [Related]
17. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system.
Chen C; Zhang C; Jin Z; Wu B; Xu T
Int J Clin Pharm; 2022 Jun; 44(3):689-697. PubMed ID: 35449347
[TBL] [Abstract][Full Text] [Related]
18. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
Nebhan CA; Cortellini A; Ma W; Ganta T; Song H; Ye F; Irlmeier R; Debnath N; Saeed A; Radford M; Alahmadi A; Diamond A; Hoimes C; Ramaiya N; Presley CJ; Owen DH; Abou Alaiwi S; Nassar A; Ricciuti B; Lamberti G; Bersanelli M; Casartelli C; Buti S; Marchetti P; Giusti R; Filetti M; Vanella V; Mallardo D; Macherla S; Sussman TA; Botticelli A; Galetta D; Catino A; Pizzutilo P; Genova C; Dal Bello MG; Kalofonou F; Daniels E; Ascierto PA; Pinato DJ; Choueiri TK; Johnson DB; Marron TU; Wang Y; Naqash AR
JAMA Oncol; 2021 Dec; 7(12):1856-1861. PubMed ID: 34734989
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
